Tumour escape mechanisms and their therapeutic implications in combination tumour therapy

Cell Biology International

Volumn 34, Issue 5, 2010, Pages 553-563

  Bhutia, Sujit K ^a   Mallick, Sanjaya K ^b   Maiti, Tapas K ^b  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Combination therapy; Immune escape; Non Immune escape; Tumour evolution

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; DNA; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HISTONE DEACETYLASE; INTERLEUKIN 2; IPILIMUMAB; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; MITOMYCIN C; OBLIMERSEN; OXALIPLATIN; PROTEIN BCL 2; SAMARIUM 153; STRONTIUM 89; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENE MUTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MELANOMA; MONOTHERAPY; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CARCINOMA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; GENETIC EPIGENESIS; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

APOPTOSIS; CANCER VACCINES; COMBINED MODALITY THERAPY; EPIGENESIS, GENETIC; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTES; NEOPLASMS; TUMOR ESCAPE;

EID: 77955291016     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090206     Document Type: Review

References (101)

1. Aggarwal BB, Shishodia S, Sandur S, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
2. Ahlers CM, Camphausen K, Citrin D, Arlen PM, Gulley JL. A pilot trial of a carcinoembryonic antigen/TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. Clin Colorectal Cancer 2006;6:72-5.
3. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9.
4. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from selfdestruction after degranulation. J Exp Med 2002;196:493-503.
5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
6. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45.
7. Beissert S, Schwarz A, Schwarz T. Regulatory T cells. J Invest Dermatol 2006;126:15-24.
8. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007;67:8847-55.
9. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16.
10. Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, Ostrand-Rosenberg S. Tumor-associated myeloid-derived suppressor cells. In: Prendergast GC, Jaffee EM, editors. Cancer Immunotherapy: Immune Suppression and Tumour Growth. New York: Academic Press; 2007. p. 309-31.
11. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37.
12. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
13. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6.
14. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005;23:8950-8.
15. Cretney E, Takeda K, Yagita H., Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNFrelated apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-61.
16. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.
17. Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005;105:3206-13.
18. Daya-Grosjean L, Sarasin A. The role of UV induced lesions in skin carcinogenesis. Mutat Res 2005;571:43-56.
19. Degenhardt K, Mathew R, Beaudoin B. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006;10:51-64.
20. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
21. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004a;21: 137-48.
22. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004b;22:329-60.
23. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-20.
24. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.
25. Emens LA, Jaffee EM. Immunotherapy and cancer therapeutics: why partner? In: Prendergast GC, Jaffee EM, editors. Cancer Immunotherapy: Immune Suppression and Tumour Growth. New York: Academic Press; 2007. p. 207-233.
26. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80.
27. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94.
28. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-1203.
29. Glick, AB, Yuspa SH. Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. Semin Cancer Biol 2005;15:75-83.
30. Gonzalez R, Lewis K, Samlowski W et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2007; 25th ASCO Annual Meeting Proceedings
31. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002;419:734-8.
32. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25:B89-96.
33. Gulley JL, Arlen PM, Bastian A. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
34. Gyorffy S, Palmer K, Podor TJ, Hitt M, Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined antiangiogenesis and immunotherapy. J Immunol 2001;166:6212-17.
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
36. Hartmann G, Bidlingmaier M., Eigler A., Hacker U, Endres S. Cytokines and therapeutic oligonucleotides. Cytokines Cell Mol Ther 1997;3:247-56.
37. Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006;66:9349-51.
38. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006;8:1369-75.
39. Hirst CE, Buzza MS, Bird CH, Warren HS, Cameron PU, Zhang M. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is upregulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J Immunol 2003;170:805-15.
40. Hodi, FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008;105:3005-10.
41. Huang X, Raskovalova T, Lokshin A, Krasinskas A, Devlin J, Watkins S et al. Combined antiangiogenic and immune therapy of prostate cancer. Angiogenesis 2005;8:13-23.
42. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu Rev Pathol Mech Dis 2009;4:229-49.
43. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
44. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumorantagonizing genes. Genes Chromosomes Cancer 2003;38: 307-21.
45. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
46. Khong HT, Wang QJ, Rosenberg S. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-90.
47. Klein G, Imreh S, Zabarovsky, ER. Why do we not all die of cancer at an early age? Adv Cancer Res 2007;98:1-16.
48. Klein G. Cancer, apoptosis, and non-immune surveillance. Cell Death Differ 2004;11:13-17.
49. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY et al. A combination of chemoimmunotherapies can efficiently break selftolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007;67:7477-86.
50. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 2007;97:1-5.
51. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74.
52. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005;65:11156-63.
53. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
54. Ma L, Luo L, Qiao H, Dong X, Pan S, Jiang H et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2007;46:98-106.
55. MacKie RM Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003;348:567-8.
56. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
57. Malmberg KJ, Ljunggren HG. Escape from immune- and non-immunemediated tumor surveillance. Semin Cancer Biol 2006;16:16-31.
58. Martin-Orozco N, Dong C. Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol 2007;17:288-98.
59. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008;118:376-86.
60. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
61. Mellor L, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
62. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35.
63. Modrak DE, Gold DV, Goldenberg DM, Blumenthal RD. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumor Biol 2003;24:32-9.
64. Moniz M, Yeatermeyer J, Wu TC. Control of cancers by combining antiangiogenesis and cancer immunotherapy. Drugs Today (Barc) 2005;41:471-94.
65. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007;67:371-380.
66. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102:964-71.
67. Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 2001;23:263-72.
68. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, Takahashi K. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006;32: 363-70.
69. Piemonti L, Zerbi A, Di Carlo V. Strategies for tumor immune escape. Drugs Today 2003;39:701-24.
70. Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res 2007;67:3500-4.
71. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
72. Rak J, Mitsuhashi Y, Sheehan C, Krestow JK, Florenes VA, Filmus J, Kerbel RS. Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia 1999;1:23-30.
73. Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 2004;3:969-76.
74. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med 2006;79:123-30.
75. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 2000;61:1001-12.
76. Rubin H. Microenvironmental regulation of the initiated cell. Adv Cancer Res 2003;90:1-62.
77. Sarasin A, Stary A. Human cancer and DNA repair-deficient diseases. Cancer Detect Prev 1997;21;406-11.
78. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization and commentary. Cancer Immun 2004;4:1.
79. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.
80. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
81. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000;50:273-9.
82. Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW. Synergistic antitumor activity of immune strategies combined with radiation. Front Biosci 2007;12:4900-10.
83. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
84. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
85. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192: 755-60.
86. Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasLFas interaction. Blood 2002;2100:4098-107.
87. Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-34.
88. Sun X, Kanwar JR, Leung E, Smyth MJ. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther 2001;8:719-727.
89. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9.
90. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB10401+ patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
91. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 2007:28:491-6.
92. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2008;15:21-8.
93. van der Most RG, Nowak AK, Lake RA. Immune stimulatory features of classical chemotherapy. In: Prendergast GC, Jaffee EM,, editors. Cancer Immunotherapy: Immune Suppression and Tumour Growth. New York: Academic Press; 2007. p. 235-56.
94. Vereecque R, Buffenoir G, Gonzalez R., Hetuin D, Bauters F, Fenaux P, Quesnel B. Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells. Br J Haematol 2000;108(4):825-831.
95. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039-46.
96. Wansley E, Chakraborty M, Carrasquillo J et al. Use of samarium-153 (Quadramet) to modulate phenotype and enhance killing of tumor cells. AACR Annual Meeting Proceedings 2006.
97. Watters D Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol Cell Biol 1999;77:263-71.
98. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES et al. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161-9.
99. Wong JYC, Chu DZ, Williams LE. A phase I trial of (90) Y-DOTA-anti-CEA chimeric T84 66 (cT84. 66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm 2006;21:88-100.
100. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-27.
101. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.